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ABSTRACT Drug-induced lupus erythematosus (DI-LE) is an autoimmune 
condition secondary to a recent pharmacological intervention. There are no 
established specific diagnostic criteria for DI-LE, and the disease is recognized 
based on the medical history of the patient. Typically, the onset is closely re-
lated to a recent drug exposure, and the disease terminates after discontinu-
ation of the inducing factor. The most frequent form of DI-LE is drug-induced 
subacute cutaneous lupus erythematosus (DI-SCLE). There has been an in-
creasing number of drugs which are suspected to provoke SCLE lesions. Pre-
viously, systemic beta-blockers (antiarrhythmics and antihypertensives) were 
shown to be inducing factors of SCLE, however data regarding its topical us-
age are lacking in the literature. We present the case of a 78-year-old woman 
who developed annular polycyclic erythema in sun-exposed areas of the skin, 
four weeks after an initiation of topical timolol treatment of glaucoma. A reso-
lution of cutaneous manifestations within only a few weeks after a cessation 
of the agent confirmed a clinical suspicion of drug-induced SCLE. 
KEY WORDS: subacute cutaneous lupus erythematosus, topical, timolol, beta 
blocker, drug-induced
INTRODUCTION
Drug-induced lupus erythematosus (DI-LE) is an 
autoimmune condition secondary to a recent phar-
macological intervention. There are no established 
specific diagnostic criteria for DI-LE, and the disease 
is recognized based on the medical history of the 
patient. Typically, the onset is closely related to a re-
cent drug exposure and the disease terminates after 
discontinuation of the inducing factor. DI-LE, likewise 
an idiopathic form of lupus erythematosus, may mani-
fest as a systemic or cutaneous disease (1,2). However, 
drugs can be inducing factors for all clinical variants, 
the most frequent form is drug-induced subacute cu-
taneous lupus erythematosus (DI-SCLE). Clinically, an-
nular polycyclic or papulosquamous lesions develop 
in sun-exposed areas of the skin soon after a new 
pharmacological intervention (2,3). We present a case 
of SCLE which developed four weeks after an initiation 
of topical timolol treatment of glaucoma.
CASE REPORT
A 78-year-old woman was admitted to our Der-
matology Department due erythematous skin lesions 
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(Figure 1). Cutaneous findings were located predomi-
nantly in sun-exposed areas and had a tendency to 
form annular, polycyclic shapes. Retrospectively, the 
lesions started to appear one-month before on the 
skin of the lower neck area (Figure 2), extending to 
the back and upper extremities. The skin under un-
derwear was intact (Figure 3).
Initially, cutaneous pathologies were suggestive 
of photosensitivity reaction. They did not respond 
well to antihistamines and topical corticosteroids. 
There was a suspicion of allergy to drugs prescribed 
due to the patient’s comorbidities, but no systemic 
agents had been modified over the previous months. 
The patient was receiving antihypertensive drugs 
(losartan, nebivolol), acetylsalicylic acid, metformin 
due to type 2 diabetes mellitus, and lipid-lowering 
therapy. Interestingly, four weeks earlier the patient 
had commenced topical treatment with timolol for 
glaucoma. It was not initially suspected as a causative 
factor, particularly due to a lack of periorbital cutane-
ous manifestations.
There was only a mild decrease of white blood 
count – 3.49 G/L (N: 4.00-10.00 G/L) in laboratory 
tests. An assay of antinuclear antibodies revealed a 
presence of anti-Ro/SSA. Anti-dsDNA or anti-histone 
antibodies were not identified. A skin biopsy taken 
from the neck showed a fair hydropic degeneration 
of the basilar epithelial layer and a prominent edema 
of the dermis. Both anti-Ro/SSA antibodies and the 
histopathology were suggestive for SCLE. 
Chloroquine was contraindicated because the 
patient presented retinopathy in fundus examina-
tion caused by long-term diabetes. Systemic corti-
costeroids were also undesirable due to diabetes. 
The Naranjo algorithm determined the probable 
adverse drug reaction was the recently-introduced 
drug, and the decision to cease topical timolol was 
made. It was switched to bimatoprost. The therapy 
with antihistaminic and topical corticosteroids was 
Table 1. Drugs identified as agents provoking systemic lupus erythematosus (SCLE)
SYSTEmIC LUPUS ERYThEmATOSUS
Hydralazine, procainamide, isoniazid and minocycline
SUBACUTE CUTANEOUS LUPUS ERYThEmATOSUS
Antihypertensives – about 34%
Diuretics – Hydrochorothiazide
Calcium channel blockers – Diltiazem, verapamil
Oral beta blockers – Oxprenolol






Nonsteroidal anti-inflammatory drugs and other
ChRONIC CUTANEOUS LUPUS ERYThEmATOSUS
Fluorouracile agents, Nonsteroidal anti-inflammatory drugs, TNF-alpha antagonists
Figure 1. Erythematous lesions with a tendency to form an-
nular polycyclic shapes. Figure 2. Neck area affected by lesions.
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continued. Soon after the discontinuation of topical 
timolol, cutaneous lesions gradually started to resolve, 
and within four weeks only slight erythema was no-
ticeable.
DISCUSSION
A development of drug-induced systemic lupus 
erythematosus was first reported in 1952 after an 
exposure to hydralazine. Its subacute cutaneous vari-
ant was later described in 1985 in association with 
hydrochlorthiazde (4,6). The list of drugs identified to 
be inducing factors for LE has been expanded since 
(Table 1) (1,4).
Typically, DI-LE affects women (about 75% of 
cases), predominantly in the sixth decade of life. Cu-
taneous manifestations usually occur in sun-exposed 
areas, preferentially on the upper neck, shoulders, 
and the upper extremities (3,4). It is assumed that a 
photosensitive reaction is triggered by a drug as an 
isomorphic response; however, it occurs only in pre-
disposed individuals. Increased risk of photosensitiv-
ity is a characteristic feature of most drugs which are 
suspected to be inducing factors for SCLE. Conceiv-
ably, a concomitant existence of other factors can en-
hance photosensitive response to some drugs. Those 
could be factors other than drugs photosensitizing 
chemicals, cigarettes, or infections; however, none of 
them were reported in our patient (2,4).
The delay between starting with timolol exposure 
and the development of skin lesions was approxi-
mately four weeks. In the literature, the mean time 
of latency varies from only 3 days to as much as 11 
years. The resolution of cutaneous findings may last 
from only 1 week up to several months after the with-
drawal of the inducing drug (4).
To the best of our knowledge, there are no case 
reports of subacute cutaneous lupus erythematosus 
induced by use of ophthalmic drops available in the 
English literature. Induction of systemic LE was pre-
viously reported by Zamber et al. A male patient de-
veloped fever, malaise, pleurisy, and recurrent sterile 
pleural effusions while taking no medication other 
than timolol. Anti-histone antibodies were positive, 
while antibodies to native DNA were absent. A dis-
continuation of ophthalmic treatment promptly im-
proved the symptoms as in case of our patient (7).
Topical timolol, like systemic drugs, generated 
anti-Ro/SSA antibodies. Anti-histone antibodies are 
rarely found (3). Homberg et al. classified timolol as 
a weak inducer of iatrogenic lupus when compared 
with major drugs: procainamide, high doses of hy-
dralazine, and D-penicillamine (8). However, topical 
beta-blockers are suspected of increasing antinuclear 
antibodies in the patients sera. (9)
Almost complete resolution of skin lesions after 
four weeks strongly suggests a causative role of timo-
lol for the development of cutaneous lupus in our pa-
tient. It proves that the most effective management 
in DI-LE is a discontinuation of the inducing drug 
without the need for additional immunosuppressive 
treatment (1,4). 
CONCLUSION
Our case report emphasizes that DI-LE is also as-
sociated with the use of topical agents even with-
out oral intake. It is always important to consider all 
pharmacological interventions, not necessarily only 
systemic ones, which enables the elimination of the 
triggering factor without immunosuppressive treat-
ment.
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